Treatment of gastric cancer

被引：0

作者：

Michele Orditura ^{[1
]}

Gennaro Galizia ^{[2
]}

Vincenzo Sforza ^{[1
]}

Valentina Gambardella ^{[1
]}

Alessio Fabozzi ^{[1
]}

Maria Maddalena Laterza ^{[1
]}

Francesca Andreozzi ^{[1
]}

Jole Ventriglia ^{[1
]}

Beatrice Savastano ^{[1
]}

Andrea Mabilia ^{[2
]}

Eva Lieto ^{[2
]}

Fortunato Ciardiello ^{[1
]}

Ferdinando De Vita ^{[1
]}

机构：

[1] Division of Medical Oncology,Dipartimento di Medicina,Clinica e Sperimentale ‘F. Magrassi-A. Lanzara’,Seconda Università degli Studi di Napoli,80131 Naples,Italy

[2] Divisione di Chirurgia Oncologia,Dipartimento di Scienze Anestesiologiche,Chirurgiche e delle Emergenze,Seconda Università degli Studi di Napoli,80131 Naples,Italy

来源：

World Journal of Gastroenterology | 2014年 / 07期

关键词：

Gastric cancer; Surgery; Radiotherapy; Adjuvant chemotherapy; Palliative chemotherapy; Chemoradiation;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100214 ;

摘要：

The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance status

引用

页码：1635 / 1649

页数：15